OakChart

Polaryx Therapeutics Inc

PLYXHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

1.950.00 (0.00%)
2026-11-12 14:11 CET
Market cap
97.20 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-6.85 USD m
Free cash flow, TTM
-5.81 USD m
EPS diluted, TTM
-0.14
P/E
-
Compare

Price

PLYX against its 20 and 50-day averages
2050missearnings
Patternshover a marker to name it
R mean, own scalesmoothed
RS 0R -0.05Price-0.05-0.042.003.004.005.00623K1.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PLYXclose 1.9520-day 1.8650-day 1.971.9552w low

96.0% under the 52-week high of 48.91 on 2 Feb 2026. 52-week low 1.69 on 3 Nov 2026. Last 15 sessions, 17.8% high to low

Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average

Profile

PLYX
52-week range, 1% of the way up
1.6948.91

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

Employees11
IPOFeb 02, 2026
ATR, 14d0.12
Rel volume0.00
Short float2.19%
Insider own87.33%
Inst own4.34%

Snapshot

6 groups

Valuation

Index-
Market Cap97.20M
Enterprise Value85.66M
Income-6.85M
Sales0.00M
Book/sh0.22
Cash/sh0.23
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees11
IPOFeb 02, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B8.89
P/C8.42
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio13.53
Current Ratio13.53
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.14
EPS next Y-0.28
EPS next Q-0.04
EPS this Y8.33%
EPS next Y-54.55%
EPS next 5Y-23.86%
EPS past 3/5Y-54.22% -
Sales past 3/5Y- -
EPS Y/Y TTM9.65%
Sales Y/Y TTM-
EPS Q/Q-34.27%
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.0.00% -

Ownership

Insider Own87.33%
Insider Trans0.20%
Inst Own4.34%
Inst Trans-1.12%
ROA-89.21%
ROE-96.56%
ROIC-62.61%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA204.92%
SMA50-1.21%
SMA200-45.51%
Trades-

Technical

Shs Outstand49.85M
Shs Float6.31M
Short Float2.19%
Short Ratio2.72
Short Interest0.14M
52W High48.91 -96.01%
52W Low1.69 15.38%
Volatility6.68% 6.12%
ATR (14)0.12
RSI (14)53.78
Beta-
Rel Volume0.00
Avg Volume50.85K
Volume0

Performance

Perf Week8.33%
Perf Month0.52%
Perf Quarter-22.00%
Perf Half Y-42.05%
Perf YTD-95.67%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price7.67
Prev Close1.95
Price1.95
Change %0.00%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Aug 13, 2026InitiatedRRaymond JamesStrong Buy$6+207.7%
Jul 09, 2026InitiatedHH.C. WainwrightBuy$7+259.0%
Feb 27, 2026InitiatedMMaxim GroupBuy$10+412.8%

Peers

Mkt cap
TickerCompanyMkt cap
ZVRAZevra Therapeutics Inc720.01M
PLXProtalix BioTherapeutics Inc263.92M
RGNXRegenxbio Inc552.79M
PASGPassage Bio Inc12.87M
ABEOAbeona Therapeutics Inc133.64M
DNLIDenali Therapeutics Inc3.13B
NGNENeurogene Inc519.59M
RAREUltragenyx Pharmaceutical Inc1.72B
TSHATaysha Gene Therapies Inc1.42B
BMRNBiomarin Pharmaceutical Inc11.31B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Yang Alex Keun MoChief Executive OfficerMay 27 '26Buy4.0788,453360,00424,233,249May 28 08:00 PM
Landis G. MichaelChief Financial OfficerFeb 18 '26Buy2.792,8677,991228,225Feb 20 04:41 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 38
  • Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200 (GlobeNewswire) +7.78%
  • Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer (GlobeNewswire)
  • Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial (GlobeNewswire) +6.42%
  • Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial (GlobeNewswire) +21.51%
  • Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards (GlobeNewswire)
  • Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference (GlobeNewswire)
  • Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial (GlobeNewswire) -7.54%
  • Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care (GlobeNewswire)
  • Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
  • Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) (GlobeNewswire)
  • Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events (GlobeNewswire) -19.27%
  • Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders (GlobeNewswire)
  • Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans (Benzinga) +64.32%
  • Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-0.035-0.035-0.0300.000.004
2026Q12026-06-03-0.050-0.020-0.0500.00-1
2025Q42026-02-25-0.130--0.032---
2026Q3---0.043--0.003
2026Q4---0.053--0.003
2027Q1---0.070--0.003
2027Q2---0.070--0.003
2027Q3---0.073--0.003
2027Q4---0.070--0.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-0.200--0.200--
2026FY--0.183--0.00
2027FY--0.283--0.00
2028FY--0.380--0.00
2029FY--0.275--8.50
2030FY-0.180--43.11

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-092000.000.000.00
2026Q3S2026-11-011000.000.000.00
2026Q3S2026-10-162000.000.000.00
2026Q3S2026-09-023000.000.000.00
2026Q3S2026-08-123000.000.000.00
2026Q3S2026-07-242000.000.000.00
2026Q3S2026-07-081000.000.000.00
2026Q3R2026-11-01200-0.05-0.06-0.03
2026Q3R2026-09-02300-0.04-0.06-0.03
2026Q3R2026-08-14300-0.04-0.06-0.03
2026Q3R2026-08-12200-0.05-0.06-0.04
2026Q3R2026-07-30100-0.04-0.04-0.04
2026Q3R2026-07-24200-0.04-0.04-0.03
2026Q3R2026-06-03100-0.03-0.03-0.03

Estimate history

EPS, annual-0.08-0.641-0.19-0.1442
Period202320242025TTM
EPS, quarterly-0.026-0.016-0.015-0.107-0.021-0.03-0.032-0.054-0.029
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000
Period202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual47.34347.34347.34349.846
Period202320242025MRQ
Shares, quarterly47.34347.34347.34347.34347.34347.34347.34347.34349.846
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Total Revenue0.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.00
Gross Profit0.000.000.000.00
Selling, General and Administrative Excl. Other5.227.824.353.78
Research and Development2.476.272.812.77
Other Operating Expense0.000.000.000.00
Operating Income-5.22-7.82-4.35-3.78
Interest Expense0.000.00--
Unusual Expense1.631.1626.000.00
Net Income Before Taxes-6.85-8.98-30.36-3.78
Income Taxes0.000.000.000.00
Consolidated Net Income-6.85-8.98-30.36-3.78
Net Income From Continuing Operations-6.85-8.98-30.36-3.78
Net Income-6.85-8.98-30.36-3.78
EPS (Recurring)-0.12-0.17-0.26-0.08
EPS (Basic, Before Extraordinaries)-0.14-0.19-0.64-0.08
EPS (Diluted)-0.14-0.19-0.64-0.08
EBITDA-5.22-7.82-4.35-3.78
Non-Operating Income (Expense)0.000.000.000.00
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense0.634.722.403.24
Shares Outstanding49.8547.3447.3447.34
Market Capitalization97.2097.20--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other1.381.960.910.970.885.050.720.77
Research and Development0.720.680.560.510.484.720.350.35
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.38-1.96-0.91-0.97-0.88-5.05-0.72-0.77
Interest Expense0.000.000.000.000.000.00--
Unusual Expense0.000.590.580.460.120.000.000.00
Net Income Before Taxes-1.38-2.54-1.50-1.43-1.01-5.05-0.72-0.77
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.38-2.54-1.50-1.43-1.01-5.05-0.72-0.77
Net Income From Continuing Operations-1.38-2.54-1.50-1.43-1.01-5.05-0.72-0.77
Net Income-1.38-2.54-1.50-1.43-1.01-5.05-0.72-0.77
EPS (Recurring)-0.03-0.05-0.02-0.02-0.02-0.11-0.02-0.02
EPS (Basic, Before Extraordinaries)-0.03-0.05-0.03-0.03-0.02-0.11-0.02-0.02
EPS (Diluted)-0.03-0.05-0.03-0.03-0.02-0.11-0.02-0.02
EBITDA-1.38-1.96-0.91-0.97-0.88-5.05-0.72-0.77
Non-Operating Income (Expense)0.000.000.000.000.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.000.470.060.110.114.450.090.00
Shares Outstanding49.8547.3447.3447.3447.3447.3447.3447.34
Market Capitalization97.20357.92312.94-----

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY
Cash & Short Term Investments5.144.620.00
Short Term Receivables0.000.000.00
Inventories0.000.000.00
Other Current Assets0.030.382.31
Total Current Assets5.175.002.31
Net Property, Plant & Equipment0.000.000.00
Total Investments and Advances0.000.000.00
Intangible Assets0.000.000.00
Deferred Tax Assets0.250.470.00
Other Assets0.000.000.00
Total Assets5.425.472.31
Short Term Debt Incl. Current Port. of LT Debt0.000.000.13
Accounts Payable0.470.070.47
Other Current Liabilities0.140.220.44
Total Current Liabilities0.600.291.04
Long Term Debt0.000.000.00
Provision for Risks Charges0.000.000.00
Deferred Tax Liabilities0.250.470.00
Other Liabilities0.000.000.00
Total Liabilities0.850.761.04
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value0.000.000.00
Common Equity4.574.711.28
Total Shareholders Equity4.574.711.28
Accumulated Minority Interest0.000.000.00
Total Equity4.574.711.28
Total Liabilities & Stockholders Equity5.425.472.31
Book Value Per Share0.100.100.03
Tangible Book Value Per Share0.100.100.03
Full-Time Employees11--
Price to Book Ratio8.89--
Return on Assets-165.04-780.06-
Return on Equity-193.70-1,013.73-
Return on Invested Capital-196.82-644.23-295.93
Quick Ratio8.5517.302.23
Current Ratio8.5517.302.23

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Net Income-6.85-8.98-30.36-3.78
Other Funds (Non Cash)0.634.7228.403.24
Funds from Operations-6.22-4.26-1.95-0.54
Extraordinary Item0.000.000.000.00
Changes in Working Capital0.410.32-0.620.37
Cash from Operating Activities-5.81-3.94-2.57-0.17
Capital Expenditures0.000.000.000.00
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments0.000.000.000.00
Purchase of Investments0.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.00
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities0.000.000.000.00
Cash Dividends Paid0.000.000.000.00
Change in Capital Stock14.054.477.320.00
Repurchase of Common Pref Stock0.000.000.000.00
Sale of Common Pref Stock14.054.477.320.00
Proceedsfrom Stock Options14.054.477.320.00
Issuance or Reduction of Debt, Net0.000.00-0.130.13
Change in Long Term Debt0.000.000.000.00
Issuance of Long Term Debt0.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00
Other Financing Activities Uses0.000.000.000.00
Cash from Financing Activities14.054.477.190.13
Net Change in Cash8.240.524.62-0.04
Free Cash Flow-5.81-3.94-2.57-0.17
Preferred Dividends (Cash Flow)-0.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments11.543.085.145.753.304.16
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.270.420.030.240.240.28
Total Current Assets11.813.505.175.983.544.44
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets--0.25---
Other Assets0.000.000.000.000.000.00
Total Assets11.813.505.425.983.544.44
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.680.850.470.500.160.06
Other Current Liabilities0.190.160.140.190.140.13
Total Current Liabilities0.871.010.600.680.300.18
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.25---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.871.010.850.680.300.18
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity10.942.494.575.303.254.25
Total Shareholders Equity10.942.494.575.303.254.25
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity10.942.494.575.303.254.25
Total Liabilities & Stockholders Equity11.813.505.425.983.544.44
Book Value Per Share0.220.050.100.110.070.09
Tangible Book Value Per Share0.220.050.100.110.070.09
Full-Time Employees--11111111
Price to Book Ratio8.8978.4168.55---
Return on Assets-89.21-163.15-165.04---
Return on Equity-96.56-192.17-193.70---
Return on Invested Capital-12.62-102.25-32.75-26.98-31.04-118.79
Quick Ratio13.533.458.558.7711.9723.99
Current Ratio13.533.458.558.7711.9723.99

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.38-2.54-1.50-1.43-1.01-5.05
Other Funds (Non Cash)0.000.470.060.110.114.45
Funds from Operations-1.38-2.08-1.44-1.32-0.90-0.60
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.010.01-0.050.430.04-0.11
Cash from Operating Activities-1.37-2.06-1.49-0.89-0.86-0.71
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock9.830.000.893.330.000.25
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock9.830.000.893.330.000.25
Proceedsfrom Stock Options9.830.000.893.330.000.25
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities9.830.000.893.330.000.25
Net Change in Cash8.46-2.06-0.602.44-0.86-0.46
Free Cash Flow-1.37-2.06-1.49-0.89-0.86-0.71

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.19%0.1M6.3M58.44K
2026-10-151.87%0.1M6.3M71.20K
2026-09-302.27%0.1M6.3M81.92K
2026-09-152.96%0.2M6.3M94.63K
2026-08-313.24%0.2M6.3M125.91K
2026-08-146.21%0.2M4.0M198.58K
2026-07-316.40%0.3M4.0M207.08K
2026-07-157.51%0.3M4.1M216.59K
2026-06-3010.01%0.4M4.1M234.13K
2026-06-1511.38%0.4M3.9M368.81K
2026-05-298.95%0.3M3.9M928.68K
2026-05-154.64%0.2M3.9M1.79M
2026-04-306.87%0.3M3.9M1.82M
2026-04-156.13%0.2M3.9M2.18M
2026-03-3110.14%0.4M3.9M2.67M
2026-03-1311.19%0.4M3.9M3.41M
2026-02-275.60%0.2M3.9M3.25M
2026-02-130.64%0.0M4.1M169.68K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-148-KCurrent report2026-09-10SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-28ARSAnnual report to security holders. 2025-12-31SEC
2026-07-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-07-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-10SEC
2026-07-24S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-218-KCurrent report2026-07-19SEC
2026-07-178-KCurrent report2026-07-16SEC
2026-05-284Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-288-KCurrent report2026-05-27SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-03-2410-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-204Statement of changes in beneficial ownership of securities2026-02-18SEC
2026-02-05SCHEDULE 13DSEC
2026-02-02424B4SEC
2026-01-29EFFECTEffectiveness filing by commission orderSEC
2026-01-293Initial statement of beneficial ownership of securities2026-01-29SEC
2026-01-293Initial statement of beneficial ownership of securities2026-01-29SEC
2026-01-293Initial statement of beneficial ownership of securities2026-01-29SEC
2026-01-293Initial statement of beneficial ownership of securities2026-01-29SEC
2026-01-293Initial statement of beneficial ownership of securities2026-01-29SEC
2026-01-293Initial statement of beneficial ownership of securities2026-01-29SEC
2026-01-293Initial statement of beneficial ownership of securities2026-01-29SEC
2026-01-28CERTSEC
2026-01-278-A12BSEC
2026-01-27S-1/ASEC
2026-01-14S-1/ASEC
2025-11-21S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2025-10-31C-UProgress UpdateSEC
2025-10-27C-UProgress UpdateSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-05360.00K100
2026-040000
2026-030000
2026-027.99K100
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC3.50%
GEODE CAPITAL MANAGEMENT, LLC0.28%
VANGUARD FIDUCIARY TRUST CO0.22%
HRT FINANCIAL LP0.17%
STATE STREET CORP0.12%
BlackRock, Inc.0.09%
JANE STREET GROUP, LLC0.07%
NORTHERN TRUST CORP0.06%
Allworth Financial LP0.02%
Vanguard Global Advisers, LLC0.01%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.10%
VANGUARD EXTENDED MARKET INDEX FUND0.30%
Fidelity Extended Market Index Fund0.13%
VANGUARD BALANCED INDEX FUND0.05%
Fidelity Total Market Index Fund0.05%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.05%
Fidelity Series Total Market Index Fund0.04%
Fidelity Nasdaq Composite Index Fund0.04%

OakChart. PLYX. Cached 15 minutes.